CONFERENCE FACULTY
About the Conference:
CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies. The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies will also be discussed.
CONFERENCE MAIN SCIENTIFIC TOPICS:
- Non-hodgkin lymphoma (NHL)
- Multiple myeloma
- Novel indications CAR T-cell therapy
- Managing toxicity of CAR-T and bispecific antibody treatment
- Real world data CAR-T
- Life after CAR T-cell therapy
With the support of*:
Major Conference Partners
*******
Level 2 Conference Partner
*******
Supporting Conference Partner
*******
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.